Infliximab biosimilar for psoriasis

Remsima (infliximab), an anti-inflammatory biologic medicine biosimilar to the anti-TNF Remicade (infliximab), has been launched in the UK


Remsima (infliximab), an anti-inflammatory biologic medicine biosimilar to the anti-TNF Remicade (infliximab), has been launched in the UK with a licence for a range of conditions, including psoriasis.
Remsima has been specifically developed to be highly similar to Remicade, which binds and blocks TNF alpha, an inflammatory substance that is overproduced in some inflammatory conditions.
Remsima was authorised by the European Medicines Agency after undergoing a comparability assessment versus Remicade. This included clinical trials involving 850 patients in 20 countries, which the manufacturers claim showed no clinically meaningful differences between the two medicines.
European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment report: Remsima (infliximab)
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Early emollient use does not prevent eczema in children, studies show

Early emollient use does not prevent eczema in children, studies show

Daily application of emollients in infancy is not effective...

Macrolide prescribing in pregnancy linked to risk of birth defects

Macrolide prescribing in pregnancy linked to risk of birth defects

Researchers have called for caution when prescribing...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Ativan and penicillamine.
Use our constantly...